Biozipcode Inc. is the central company in the medical and biotech field for which Fumihisa Kojima serves as Representative Director.

The company is engaged in research aimed at developing a fundamental treatment for diabetes, cell-targeting technology Biozipcode™, biomarkers, 5-ALA, and applied research for cancer and intractable diseases.

This initiative began with support for joint research with Shiga University of Medical Science that had continued since the days of Studio Makyu Co., Ltd.. Later, through Biozipcode Inc., it became involved in the “Regenerative Medicine Development Course” at Shiga University of Medical Science. Today, the research framework has developed into the industry-academia joint course “Department of Biocommunication Development” at Kyoto University, Graduate School of Medicine and Faculty of Medicine.

KIYAN MEDICAL Co., Ltd. is a company working toward the R&D and practical application of technologies in the medical and drug discovery fields, including diabetes, Biozipcode™ technology, cancer therapy, and BNCT.

As a Director of the company, Fumihisa Kojima is involved in collaboration with Biozipcode Inc., research aimed at developing a fundamental treatment for diabetes, applications of cell-targeting technology, and the development of medical businesses.

The company mainly conducts fundraising for research expenses and social implementation.

KIYAN PHARMA Co., Ltd. handles areas including 5-ALA, pharmaceutical APIs and intermediates, health foods, cosmetics, animal health, fertilizers, and feed. It also operates a 5-ALA manufacturing plant.

As an Executive Officer of the company, Fumihisa Kojima is involved in 5-ALA-related businesses, research on diabetes and its complications, and the consideration of clinical trial programs.

The industry-academia joint course “Department of Biocommunication Development” at Kyoto University, Graduate School of Medicine and Faculty of Medicine is a research base established as a joint research initiative with Biozipcode Inc..

By applying cell-targeting technology that selectively recognizes cells and tissues, the course aims to advance R&D for new therapies for diabetes, cancer, intractable diseases, and related areas.

It is an initiative that builds on research activities previously advanced at Shiga University of Medical Science and develops them into an industry-academia joint course at Kyoto University.

The “Regenerative Medicine Development Course” established within Shiga University of Medical Science was an important joint research base in the formation of Biozipcode Inc..

The course advanced R&D related to diabetes, cancer, autoimmune diseases, and other intractable diseases, as well as research on therapies using the cell-targeting peptide technology Biozipcode™.

It is positioned as an initiative that developed the research support that had continued since the days of Studio Makyu Co., Ltd. into full-scale university joint research through Biozipcode Inc..

Studio Makyu Co., Ltd. is a company for which Fumihisa Kojima serves as Representative Director.

The company has worked in areas including web production, DTP design, systems development, web marketing, SEO, GPGPU, blockchain-related businesses, and bioinformatics support.

It originally began with a focus on web production, advertising operations, and systems development, and later expanded into GPGPU, large-scale computing, crypto-asset mining, and research software development.

Before the establishment of Biozipcode Inc., the company had also been involved in supporting joint research with Shiga University of Medical Science. It forms part of the foundation of the current medical and biotech business.

The AI and computational science business follows the path of life informatics, bioinformatics, GPGPU, HPC, and in silico analysis that Fumihisa Kojima has been interested in since his student days.

It is positioned as a technical foundation that supports the organization of life science data using information science methods, as well as medical research, drug discovery research, Biozipcode™-related research, analysis of patent and paper information, and the structuring of research data.

Senard Co., Ltd. provides investigation and database-related services using anti-social forces screening, compliance checks, web crawling, and natural language processing.

As the company’s Chief Technology Officer, Fumihisa Kojima has been involved in collecting and organizing information related to anti-social forces, developing compliance check systems, web search systems, and investigation systems using natural language processing.

This experience also connects to the thinking behind KYC, AML, anti-social forces screening, and risk management in Web3 projects and overseas expansion.

At Japan Credit Information Service Co., Ltd., Fumihisa Kojima was involved in building databases related to anti-social forces, compliance check services, and investigation systems.

This experience later connected to the compliance check business at Senard Co., Ltd. and to the thinking behind KYC and AML frameworks in Web3-related projects.

At DMG Blockseer Japan Inc., Fumihisa Kojima was involved in blockchain analytics, AML, and FinTech compliance.

He gained experience in areas where blockchain and risk management intersect, including detection of suspicious transactions in crypto-asset transactions and support for investigations involving criminal funds and money laundering-related transactions.

Auring Ltd. is a BVI entity positioned as the issuer related to GDT.

As Representative Director / Director of Auring Ltd., Fumihisa Kojima is involved in organizing the issuer-side structure for GDT, overseas Web3 projects, token governance, medical service payments, and compliance frameworks including KYC and AML.

Auring Ltd. is organized separately from the medical research and commercialization activities handled by Biozipcode Inc., and is positioned as the company responsible for the issuance and operation side of overseas Web3 projects.

GDT is envisioned as a utility token linked to diabetes research, 5-ALA, medical tourism, biomarker testing, specialist consultations, overseas medical expansion, and related initiatives.

For overseas participants, it is organized as a mechanism to support participation in medical research and related services, payments, and community building.

In Japan, however, the design separates the pathway for purchasing 5-ALA supplements and supporting research from the sale of GDT tokens.

Holding GDT does not guarantee medical effects, treatment outcomes, price appreciation, returns, or principal.

One of the concepts that has been considered in Palau is PWD (Palau Digital Dollar) and PWDT (Palau Development Token).

PWD is envisioned as a digital payment method based on the U.S. dollar, with potential use in tourism, hotels, retail stores, international remittances, QR payments, and related areas.

These are organized as concepts separate from GDT. PWDT is envisioned as a framework to support regional development, tourism, SDGs, medical care, housing, agriculture, and blockchain-related businesses in Palau.

At present, because the VAPS bill is awaiting passage by the legislature, only the portion of this business concept related to diabetes treatment has been separated and is being advanced as the GDT Project.

In Palau, business concepts combining blockchain, digital payments, tourism, medical care, SDGs, and regional development have been explored.

Palau has beautiful nature, marine resources, and tourism resources. At the same time, it faces challenges related to accommodation, housing, waste management, agriculture, food self-sufficiency, education, and the development of medical personnel.

In addition, diabetes, obesity, and lifestyle-related diseases are among Palau’s serious social challenges. For this reason, it is meaningful in Palau to create a new medical model that combines not only tourism and regional development, but also research aimed at developing a fundamental treatment for diabetes, prevention, dietary improvement, and medical personnel training.

Precisely because Palau is a small country with a population of about 20,000 people, it can present tourism, medical care, payments, and regional development as an integrated model. If demonstration efforts in Palau function well, the model may also be applicable to other island nations and small states.

In the UAE and GCC region, business expansion is being considered in areas related to medicine, Web3, investment, medical tourism, 5-ALA, pre-disease (me-byo), and longevity.

Dubai is a place where medicine, tourism, investment, technology, and international business converge, and it is also important as a base for expansion across the GCC.

The Global Medical and Pre-Disease (Me-byo) Project envisions a medical model centered on the UAE that combines a treatment center aiming to cure diabetes, an advanced precision pre-disease (me-byo) checkup, a 24/7/365 monitoring service, 5-ALA, Biozipcode™, longevity, and medical tourism.

This project does not guarantee that diabetes will necessarily be cured, but the business plan is centered on treatments aiming for a diabetes cure with 5-ALA as a key component.

It places pre-disease (me-byo), testing, lifestyle improvement, physician evaluation, and continuous monitoring at the center, and aims to connect these step by step to R&D-stage fundamental treatments for diabetes.

At Luck Cue Co., Ltd., Fumihisa Kojima was involved in building crypto-asset mining farms, selling GPU rigs, developing automated cryptocurrency trading software, operating web media, and conducting web marketing.

This was a period in which he gained practical experience in GPGPU and blockchain, which later connected to Web3-related businesses.

At Merchant Bankers Co., Ltd., Fumihisa Kojima served as Head of IT Strategy and was involved in blockchain, FinTech, NFTs, web marketing, and fundraising support for companies.

Through experience promoting business on the side of a listed company, he also had the opportunity to learn perspectives related to capital policy, IR, partnerships, investor presentations, and business management.